Table 1. Characteristics of SARS-CoV-2 index cases, by vaccination status of the index and characteristics of contacts, by vaccination status of the contact, the Netherlands, August–September 2021 (n = 4,921 index cases, n= 7,771 contacts).

Characteristics	Index cases						Household contacts
	Unvaccinated		Partly vaccinated		Fully vaccinated		Unvaccinated		Partly vaccinated		Fully vaccinated
Total	2,641		540		1,740		2,941		641		4,189
	n	%	n	%	n	%	n	%	n	%	n	%
Gender
Female	1,480	56	280	52	871	50	1,517	52	313	49	2,106	50
Male	1,161	44	260	48	869	50	1,379	47	320	50	2,026	48
Unknown/other	0	0	0	0	0	0	45	2	8	1	57	1
Age group (years)
12–17	1,005	38	174	32	45	3	903	31	172	27	127	3
18–29	823	31	229	42	549	32	718	24	216	34	673	16
30–49	616	23	101	19	438	25	910	31	176	27	1,460	35
50–74	183	7	33	6	631	36	383	13	77	12	1,841	44
≥ 75	14	1	3	1	77	4	27	1	0	0	88	2
Vaccine received
Comirnatya	NA	NA	483	89	963	55	NA	NA	505	79	2,544	61
Spikevaxa	NA	NA	43	8	87	5	NA	NA	53	8	389	9
Vaxzevriaa	NA	NA	14	3	273	16	NA	NA	4	1	350	8
Janssena	NA	NA	NA	NA	417	24	NA	NA	NA	NA	420	10
Unknown	NA	NA	0	0	0	0	NA	NA	79	12	486	12
Household composition
Two adults without children	825	31	165	31	977	56	634	22	160	25	1,173	28
Two adults with child(ren)	723	27	153	28	273	16	900	31	184	29	1,041	25
Single adult with child(ren)	573	22	78	14	83	5	496	17	79	12	309	7
Other	520	20	144	27	407	23	911	31	218	34	1,666	40
Month of notification of index case
August	1,410	53	429	79	916	53	1,542	52	486	76	2,178	52
September	1,231	47	111	21	824	47	1,399	48	155	24	2,011	48

SARS-CoV-2: severe acute respiratory syndrome coronavirus 2; NA: not applicable.

^a Comirnaty (BNT162b2 mRNA, BioNTech-Pfizer, Mainz, Germany/New York, United States); Spikevax (mRNA-1273, Moderna, Cambridge, United States); Vaxzevria (ChAdOx1 nCoV-19, Oxford-AstraZeneca, Cambridge, United Kingdom); COVID-19 Vaccine Janssen (Ad26.COV2-S, Janssen-Cilag International NV, Beerse, Belgium).

Percentages shown are column percentages.